Home LiteratureArticle Details
PMID: 8187794 Published · ppublish English Journal Article

Activity of subinhibitory concentrations of dapsone alone and in combination with cell-wall inhibitors against Mycobacterium avium complex organisms.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology ·Vol. 12 ·No. 12 ·1993-12-00 ·Pages 954-8

Rastogi N, Goh KS, Labrousse V

Abstract

MICs of dapsone (p-p'-diaminodiphenylsulfone) were determined radiometrically for ten strains each of the Mycobacterium avium complex (MAC) and Mycobacterium tuberculosis. MICs ranged from 50 to 250 micrograms/ml for Mycobacterium tuberculosis and from 2 to 100 micrograms/ml for MAC. However, at a concentration as low as 1.5 micrograms/ml dapsone significantly inhibited growth of MAC bacteria when used in combination with other drugs specifically acting at the mycobacterial cell-wall level. The latter drugs were used in subinhibitory concentrations, and included m-fluorophenylalanine (an inhibitor of mycoside-C biosynthesis), ethambutol (an inhibitor of arabinogalactan biosynthesis), and ethionamide (an inhibitor of mycolic acid biosynthesis). Using a radiometric method (Bactec 460-TB), the activity of dapsone was found to be enhanced for 2/10 strains in the presence of m-fluorophenylalanine, for 3/10 strains in the presence of ethambutol and for 5/10 strains in the presence of ethionamide. A satisfactory correlation between the radiometric data and bacterial viable counts was established.

MeSH Terms
Cell Wall/drug effects Dapsone/pharmacology Drug Combinations Ethambutol/pharmacology Ethionamide/pharmacology Microbial Sensitivity Tests Mycobacterium avium Complex/drug effects Mycobacterium tuberculosis/drug effects Phenylalanine/analogs & derivatives,pharmacology
Chemicals
Drug Combinations 3-fluorophenylalanine Phenylalanine Ethambutol Dapsone Ethionamide
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Rastogi N
Laboratoire de la Tuberculose et des Mycobactéries, Institut Pasteur, Point-à-Pitre, Guadeloupe.
Goh K S
Labrousse V
References (20)
20 references, click to expand
  1. Infections caused by Mycobacterium avium complex in immunocompromised patients: diagnosis by blood culture and fecal examination, antimicrobial susceptibility tests, and morphological and seroagglutination characteristics.
    J Clin Microbiol. 1985 Feb;21(2):168-73 PMID: 3972985
  2. Survival of patients with acquired immune deficiency syndrome and disseminated Mycobacterium avium complex infection with and without antimycobacterial chemotherapy.
    Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):557-9 PMID: 1892294
  3. Clinical pharmacokinetics of dapsone.
    Clin Pharmacokinet. 1986 Jul-Aug;11(4):299-315 PMID: 3530584
  4. Rationale of the multidrug regimens recommended by a World Health Organization Study Group on Chemotherapy of Leprosy for Control Programs.
    Int J Lepr Other Mycobact Dis. 1984 Sep;52(3):395-401 PMID: 6541207
  5. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome.
    N Engl J Med. 1991 May 9;324(19):1332-8 PMID: 2017230
  6. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis.
    Antimicrob Agents Chemother. 1990 May;34(5):759-64 PMID: 2360816
  7. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.
    Antimicrob Agents Chemother. 1991 Mar;35(3):462-70 PMID: 1828135
  8. A new analytical procedure for dapsone. Application to blood-level and urinary-excretion studies in normal men.
    Am J Trop Med Hyg. 1968 May;17(3):465-73 PMID: 5652701
  9. Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.
    Eur J Clin Microbiol. 1987 Oct;6(5):530-5 PMID: 3436314
  10. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?
    Antimicrob Agents Chemother. 1981 Nov;20(5):666-77 PMID: 6798925
  11. In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.
    Antimicrob Agents Chemother. 1991 Sep;35(9):1933-6 PMID: 1952872
  12. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.
    Antimicrob Agents Chemother. 1991 Dec;35(12):2473-80 PMID: 1667250
  13. The pharmacokinetics of dapsone after oral administration to healthy volunteers.
    Br J Clin Pharmacol. 1986 Oct;22(4):491-4 PMID: 3768260
  14. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG.
    J Gen Microbiol. 1971 Jun;66(3):379-80 PMID: 4999216
  15. Ten years of dapsone in lepromatous leprosy: clinical, bacteriological and histological assessment and the finding of viable leprosy bacilli.
    Lepr Rev. 1974 Dec;45(4):288-98 PMID: 4613977
  16. The absolute oral bioavailability of dapsone in dogs and humans.
    Int J Clin Pharmacol Ther Toxicol. 1987 Jul;25(7):396-400 PMID: 3623744
  17. Inhibition by ethambutol of mycolic acid transfer into the cell wall of Mycobacterium smegmatis.
    Antimicrob Agents Chemother. 1979 Aug;16(2):240-2 PMID: 485133
  18. Recent observations concerning structure and function relationships in the mycobacterial cell envelope: elaboration of a model in terms of mycobacterial pathogenicity, virulence and drug-resistance.
    Res Microbiol. 1991 May;142(4):464-76 PMID: 1871434
  19. The epidemiology of disseminated nontuberculous mycobacterial infection in the acquired immunodeficiency syndrome (AIDS).
    Am Rev Respir Dis. 1989 Jan;139(1):4-7 PMID: 2912355
  20. Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis.
    Antimicrob Agents Chemother. 1989 Sep;33(9):1493-9 PMID: 2817850
Article Info
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
Abbr.
Eur J Clin Microbiol Infect Dis
ISSN
0934-9723
DOI
10.1007/BF01992173
Published
1993-12-00
Pages
954-8
Language
English
Region
Germany
NLM ID
8804297
Subset
IM
External Links
PubMed source DOI: 10.1007/BF01992173 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2